CN102369201A - 增强谷氨酸能突触响应的二环酰胺衍生物 - Google Patents

增强谷氨酸能突触响应的二环酰胺衍生物 Download PDF

Info

Publication number
CN102369201A
CN102369201A CN2010800154033A CN201080015403A CN102369201A CN 102369201 A CN102369201 A CN 102369201A CN 2010800154033 A CN2010800154033 A CN 2010800154033A CN 201080015403 A CN201080015403 A CN 201080015403A CN 102369201 A CN102369201 A CN 102369201A
Authority
CN
China
Prior art keywords
compound
patient
treatment
medicine
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800154033A
Other languages
English (en)
Chinese (zh)
Inventor
R.米勒
L.J.斯特里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortex Pharmaceuticals Inc
Original Assignee
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharmaceuticals Inc filed Critical Cortex Pharmaceuticals Inc
Publication of CN102369201A publication Critical patent/CN102369201A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
CN2010800154033A 2009-02-02 2010-01-29 增强谷氨酸能突触响应的二环酰胺衍生物 Pending CN102369201A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20664209P 2009-02-02 2009-02-02
US61/206,642 2009-02-02
PCT/US2010/000255 WO2010087981A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
CN102369201A true CN102369201A (zh) 2012-03-07

Family

ID=42396261

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800154033A Pending CN102369201A (zh) 2009-02-02 2010-01-29 增强谷氨酸能突触响应的二环酰胺衍生物

Country Status (12)

Country Link
EP (1) EP2391621A4 (cg-RX-API-DMAC10.html)
JP (1) JP2012516845A (cg-RX-API-DMAC10.html)
KR (1) KR20110115139A (cg-RX-API-DMAC10.html)
CN (1) CN102369201A (cg-RX-API-DMAC10.html)
AU (1) AU2010208646A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1005316A2 (cg-RX-API-DMAC10.html)
CA (1) CA2751285A1 (cg-RX-API-DMAC10.html)
EA (1) EA018994B1 (cg-RX-API-DMAC10.html)
IL (1) IL214392A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011008060A (cg-RX-API-DMAC10.html)
SG (1) SG173168A1 (cg-RX-API-DMAC10.html)
WO (2) WO2010087980A2 (cg-RX-API-DMAC10.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331761T2 (de) * 1992-07-24 2002-09-12 The Regents Of The University Of California, Oakland Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US6166008A (en) * 1997-10-27 2000-12-26 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
JP5694765B2 (ja) * 2007-05-17 2015-04-01 コーテックス ファーマシューティカルズ， インコーポレイテッド グルタミン酸作動性シナプス反応を増強するための二置換アミド
ES2560095T3 (es) * 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas

Also Published As

Publication number Publication date
EP2391621A4 (en) 2012-07-25
EA018994B1 (ru) 2013-12-30
WO2010087981A3 (en) 2011-03-24
EA201101162A1 (ru) 2012-01-30
SG173168A1 (en) 2011-08-29
MX2011008060A (es) 2011-09-09
JP2012516845A (ja) 2012-07-26
BRPI1005316A2 (pt) 2019-09-24
WO2010087980A3 (en) 2011-02-24
IL214392A0 (en) 2011-09-27
WO2010087981A2 (en) 2010-08-05
WO2010087980A2 (en) 2010-08-05
KR20110115139A (ko) 2011-10-20
CA2751285A1 (en) 2010-08-05
EP2391621A2 (en) 2011-12-07
AU2010208646A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
CA2695742C (en) Bicyclic amides for enhancing glutamatergic synaptic responses
US8642633B2 (en) Di-substituted amides for enhancing glutamatergic synaptic responses
EP2233140A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
US8507482B2 (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
HK1163693A (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
KR20110115139A (ko) 글루타메이트성 시냅틱 반응을 향상시키기 위한 비시클릭 아미드 유도체
AU2013205446A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
HK1147677B (en) Bicyclic amides for enhancing glutamatergic synaptic responses
HK1149711A (en) Use of bicyclic amide in preparing pharmaceuticals for treatment of respiratory

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1163693

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120307

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1163693

Country of ref document: HK